ACT Genomics Statement

ACT Genomics today announced a significant upgrade to the ACTDrug® series, its next-generation sequencing (NGS) genomic profiling service. The updated panel now covers 101 clinically relevant genes and offers a seven-working-day turnaround time, designed to provide comprehensive genomic information to support physicians in making treatment decision for newly diagnosed patients with advanced or metastatic cancer.

ACT Genomics Co., Ltd.(“ACT Genomics”) today announced an update to ACTMonitor® Breast, expanding the assay to a 10-gene panel with the addition of AKT1 and PTEN biomarkers. This enhancementis designed to broaden molecular insights available to clinicians andlaboratories supporting breast cancer monitoring and care.